Compare BEDU & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEDU | ACET |
|---|---|---|
| Founded | 1994 | 1947 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 93.5M |
| IPO Year | 2017 | N/A |
| Metric | BEDU | ACET |
|---|---|---|
| Price | $2.25 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 7.4K | ★ 2.3M |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,321,752.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $0.45 |
| 52 Week High | $2.28 | $1.11 |
| Indicator | BEDU | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 30.48 |
| Support Level | $2.18 | $0.50 |
| Resistance Level | $2.28 | $0.59 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 70.00 | 4.67 |
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.